Science

David J. Benjamin: Why did sacituzumab govitecan fail in the TROPiCS-04 study for advanced urothelial carcinoma?

David J. Benjamin/X

Jan 26, 2025, 21:58

David J. Benjamin: Why did sacituzumab govitecan fail in the TROPiCS-04 study for advanced urothelial carcinoma?

David J. Benjamin, Medical Oncologist at the Hoag Family Cancer Institute, sharted a recent article by him and colleagues on X:

“Why did sacituzumab govitecan fail in the TROPiCS-04 study for advanced urothelial carcinoma?

In European Urology Oncology, we discuss the potential roles of G-CSF, dosing approaches, and differences in patient population compared to the TROPHY-U-01 trial.”

“Implications and Lessons from the Withdrawal of Sacituzumab Govitecan for Treating Advanced Urothelial Carcinoma“

Authors: David J. Benjamin, Arash Rezazadeh Kalebasty, and Nataliya Mar

David J. Benjamin

More posts featuring David J. Benjamin.

Arash Rezazadeh Kalebasty cancer David J. Benjamin European Urology Oncology Nataliya Mar OncoDaily Oncology Sacituzumab govitecan TROPHY-U-01 trial TROPiCS urothelial carcinoma

No recurrences in MSS colorectal cancer with BOT/BAL neoadjuvant immunotherapy: NEST Trial updates from ASCOGI25

Agenus announced new data highlighting BOT/BAL across multiple lines of treatment in Colorectal Cancer

President Trump has announced U.S. Withdrawal from the World Health Organization

OncoDaily Acquires CancerWorld: A New Era in Oncology Media

The Princess of Wales thanks The Royal Marsden for looking after her during her battle with cancer